Fosnetupitant
Clinical data
Other names07-PNET, fosnetupitant chloride hydrochloride
ATC code
  • None
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC31H35F6N4O5P
Molar mass688.608 g·mol−1

Fosnetupitant is a medication used for the treatment of chemotherapy-induced nausea and vomiting. It is a prodrug of netupitant.[1] It is used in combination with palonosetron hydrochloride and formulated as the salt fosnetupitant chloride hydrochloride for intravenous use.[2]

In 2018, the U.S. Food and Drug Administration approved the intravenous formulation of a fixed dose combination of fosnetupitant and palonosetron.[3][4] The combination is also approved for medical use in the European Union[5] and in Canada.[6]

References

  1. ^ Aapro M, Jordan K, Scotté F, Celio L, Karthaus M, Roeland E (2022). "Netupitant-palonosetron (NEPA) for Preventing Chemotherapy-induced Nausea and Vomiting: From Clinical Trials to Daily Practice". Current Cancer Drug Targets. 22 (10): 806–824. doi:10.2174/1568009622666220513094352. PMC 9720881. PMID 35570542.
  2. ^ "Fosnetupitant/Palonosetron (Intravenous Route)". Mayo Clinic. Archived from the original on June 8, 2022. Retrieved June 8, 2022.
  3. ^ "Fosnetupitant". DrugBank. Archived from the original on December 2, 2021. Retrieved June 8, 2022.
  4. ^ "Akynzeo- netupitant and palonosetron capsule Akynzeo- fosnetupitant and palonosetron injection". DailyMed. 28 May 2020. Archived from the original on 18 October 2020. Retrieved 18 July 2020.
  5. ^ "Akynzeo EPAR". European Medicines Agency (EMA). Archived from the original on 19 March 2020. Retrieved 9 June 2022.
  6. ^ "Akynzeo (netupitant/palonosetron) capsules" (PDF). Product Insert. Elvium Life Sciences. 31 August 2020. Archived (PDF) from the original on 2022-06-10. Retrieved 2022-06-10.

External links


More
Categories